GLENMARK Q1 FY26 Results & Earnings Analysis
Sentiment: Good
Earnings Summary
Glenmark reported modest 0.6% YoY revenue growth to INR32,644 million in Q1 FY26, with strong underlying performance masked by strategic brand rationalization. Key highlights include: India business showing robust 15.1% secondary sales growth despite 3.7% reported growth due to tail-end brand discontinuation; successful launches of innovative oncology products TEVIMBRA and BRUKINSA; landmark AbbVie partnership for ISB 2001 validating IGI's platform; and maintained leadership positions in core therapy areas. Management expects improved performance from Q3 onwards, targeting 23% EBITDA margin and double-digit growth in key markets, supported by new product launches and geographic expansion. ,,,
Management Tone
- Prepared Remarks: —
- Q&A Session: —
Growth vs Margin Focus
Strategic shift toward high-margin branded products while maintaining growth through new launches and geographic expansion. Management guiding for 23% EBITDA margin from Q3 onwards while targeting double-digit growth in key markets. ,
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited (GLENMARK) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.